184 related articles for article (PubMed ID: 19056339)
1. Distinct properties of cyclin-dependent kinase complexes containing cyclin A1 and cyclin A2.
Joshi AR; Jobanputra V; Lele KM; Wolgemuth DJ
Biochem Biophys Res Commun; 2009 Jan; 378(3):595-9. PubMed ID: 19056339
[TBL] [Abstract][Full Text] [Related]
2. Characterization of murine gammaherpesvirus 68 v-cyclin interactions with cellular cdks.
Upton JW; van Dyk LF; Speck SH
Virology; 2005 Oct; 341(2):271-83. PubMed ID: 16102793
[TBL] [Abstract][Full Text] [Related]
3. Discovery and evaluation of dual CDK1 and CDK2 inhibitors.
Payton M; Chung G; Yakowec P; Wong A; Powers D; Xiong L; Zhang N; Leal J; Bush TL; Santora V; Askew B; Tasker A; Radinsky R; Kendall R; Coats S
Cancer Res; 2006 Apr; 66(8):4299-308. PubMed ID: 16618755
[TBL] [Abstract][Full Text] [Related]
4. The development of a CDK2-docking site peptide that inhibits p53 and sensitizes cells to death.
Ferguson M; Luciani MG; Finlan L; Rankin EM; Ibbotson S; Fersht A; Hupp TR
Cell Cycle; 2004 Jan; 3(1):80-9. PubMed ID: 14657672
[TBL] [Abstract][Full Text] [Related]
5. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5.
Meijer L; Borgne A; Mulner O; Chong JP; Blow JJ; Inagaki N; Inagaki M; Delcros JG; Moulinoux JP
Eur J Biochem; 1997 Jan; 243(1-2):527-36. PubMed ID: 9030781
[TBL] [Abstract][Full Text] [Related]
6. Molecular models of cyclin-dependent kinase 1 complexed with inhibitors.
Canduri F; Uchoa HB; de Azevedo WF
Biochem Biophys Res Commun; 2004 Nov; 324(2):661-6. PubMed ID: 15474478
[TBL] [Abstract][Full Text] [Related]
7. Biochemical characterization of Cdk2-Speedy/Ringo A2.
Cheng A; Gerry S; Kaldis P; Solomon MJ
BMC Biochem; 2005 Sep; 6():19. PubMed ID: 16191191
[TBL] [Abstract][Full Text] [Related]
8. Differences in the Conformational Energy Landscape of CDK1 and CDK2 Suggest a Mechanism for Achieving Selective CDK Inhibition.
Wood DJ; Korolchuk S; Tatum NJ; Wang LZ; Endicott JA; Noble MEM; Martin MP
Cell Chem Biol; 2019 Jan; 26(1):121-130.e5. PubMed ID: 30472117
[TBL] [Abstract][Full Text] [Related]
9. Distinct activation pathways confer cyclin-binding specificity on Cdk1 and Cdk2 in human cells.
Merrick KA; Larochelle S; Zhang C; Allen JJ; Shokat KM; Fisher RP
Mol Cell; 2008 Dec; 32(5):662-72. PubMed ID: 19061641
[TBL] [Abstract][Full Text] [Related]
10. Programmed cell death protein 4 suppresses CDK1/cdc2 via induction of p21(Waf1/Cip1).
Göke R; Barth P; Schmidt A; Samans B; Lankat-Buttgereit B
Am J Physiol Cell Physiol; 2004 Dec; 287(6):C1541-6. PubMed ID: 15317660
[TBL] [Abstract][Full Text] [Related]
11. Putting one step before the other: distinct activation pathways for Cdk1 and Cdk2 bring order to the mammalian cell cycle.
Merrick KA; Fisher RP
Cell Cycle; 2010 Feb; 9(4):706-14. PubMed ID: 20139727
[TBL] [Abstract][Full Text] [Related]
12. Functions of cyclin A1 in the cell cycle and its interactions with transcription factor E2F-1 and the Rb family of proteins.
Yang R; Müller C; Huynh V; Fung YK; Yee AS; Koeffler HP
Mol Cell Biol; 1999 Mar; 19(3):2400-7. PubMed ID: 10022926
[TBL] [Abstract][Full Text] [Related]
13. Cyclin A1 is a p53-induced gene that mediates apoptosis, G2/M arrest, and mitotic catastrophe in renal, ovarian, and lung carcinoma cells.
Rivera A; Mavila A; Bayless KJ; Davis GE; Maxwell SA
Cell Mol Life Sci; 2006 Jun; 63(12):1425-39. PubMed ID: 16799873
[TBL] [Abstract][Full Text] [Related]
14. Identification of interaction partners and substrates of the cyclin A1-CDK2 complex.
Diederichs S; Bäumer N; Ji P; Metzelder SK; Idos GE; Cauvet T; Wang W; Möller M; Pierschalski S; Gromoll J; Schrader MG; Koeffler HP; Berdel WE; Serve H; Müller-Tidow C
J Biol Chem; 2004 Aug; 279(32):33727-41. PubMed ID: 15159402
[TBL] [Abstract][Full Text] [Related]
15. Cyclin A2-CDK2 regulates embryonic gene activation in 1-cell mouse embryos.
Hara KT; Oda S; Naito K; Nagata M; Schultz RM; Aoki F
Dev Biol; 2005 Oct; 286(1):102-13. PubMed ID: 16137671
[TBL] [Abstract][Full Text] [Related]
16. Different mechanisms of CDK5 and CDK2 activation as revealed by CDK5/p25 and CDK2/cyclin A dynamics.
Otyepka M; Bártová I; Kríz Z; Koca J
J Biol Chem; 2006 Mar; 281(11):7271-81. PubMed ID: 16407256
[TBL] [Abstract][Full Text] [Related]
17. Dual blockade of lipid and cyclin-dependent kinases induces synthetic lethality in malignant glioma.
Cheng CK; Gustafson WC; Charron E; Houseman BT; Zunder E; Goga A; Gray NS; Pollok B; Oakes SA; James CD; Shokat KM; Weiss WA; Fan QW
Proc Natl Acad Sci U S A; 2012 Jul; 109(31):12722-7. PubMed ID: 22802621
[TBL] [Abstract][Full Text] [Related]
18. Differential phosphorylation of T-47D human breast cancer cell substrates by D1-, D3-, E-, and A-type cyclin-CDK complexes.
Sarcevic B; Lilischkis R; Sutherland RL
J Biol Chem; 1997 Dec; 272(52):33327-37. PubMed ID: 9407125
[TBL] [Abstract][Full Text] [Related]
19. Dual regulation of the anaphase promoting complex in human cells by cyclin A-Cdk2 and cyclin A-Cdk1 complexes.
Mitra J; Enders GH; Azizkhan-Clifford J; Lengel KL
Cell Cycle; 2006 Mar; 5(6):661-6. PubMed ID: 16582612
[TBL] [Abstract][Full Text] [Related]
20. Degradation of cyclin A does not require its phosphorylation by CDC2 and cyclin-dependent kinase 2.
Yam CH; Siu WY; Lau A; Poon RY
J Biol Chem; 2000 Feb; 275(5):3158-67. PubMed ID: 10652300
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
